Shares of Nuformix plc (LON:NFX – Get Free Report) were up 1.6% on Monday . The company traded as high as GBX 0.07 ($0.00) and last traded at GBX 0.07 ($0.00). Approximately 24,372,961 shares changed hands during trading, a decline of 54% from the average daily volume of 52,647,891 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Price Performance
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The firm has a market cap of £565,323.90, a P/E ratio of -1.63 and a beta of 1.22. The stock’s 50-day simple moving average is GBX 0.05 and its two-hundred day simple moving average is GBX 0.10.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- 3 Fintech Stocks With Good 2021 Prospects
- MP Materials: Rare Earth Elements Powering the EV Boom
- How to Effectively Use the MarketBeat Ratings Screener
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- How to Invest in the Best Canadian Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
